Could a common arthritis drug shield transplant patients from a dangerous virus?

NCT ID NCT07709013

Recruiting now Disease control Sponsor: Tata Memorial Centre Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether leflunomide, a drug typically used for arthritis, can prevent cytomegalovirus (CMV) reactivation in adults with blood cancers who receive a half-matched stem cell transplant. Participants take leflunomide daily for up to six months after transplant. The study tracks how many develop significant CMV infections, organ damage, or need additional anti-CMV therapy, and monitors safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leflunomide
What this could lead to: If effective, leflunomide could offer a new way to prevent dangerous CMV infections in stem cell transplant patients, reducing organ damage and the need for additional treatments.
What could go wrong: This is a small, early-phase trial with only 22 participants, so results may not apply broadly. Leflunomide may cause side effects or fail to prevent CMV reactivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Advanced Centre for Treatment, Research and Education in Cancer
NOT_YET_RECRUITING

Navi Mumbai, Maharashtra, 410210, India
Advanced Centre for Treatment, Research and Education in Cancer
NOT_YET_RECRUITING

Navi Mumbai, Maharashtra, 410210, India

Contact

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre
RECRUITING

Navi Mumbai, Maharashtra, 410210, India

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.